Merck: Second “Not Approvable” Letter In Two Days – This Time, Cordaptive
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA nixes name, too, for anti-cholesterol niacin/laropiprant combo.
You may also be interested in...
Prasugrel: To Be (Approved) Or Not To Be
FDA will soon weigh in; the action date for Lilly/Daiichi’s Plavix competitor is June 26.
FDA Seeks Outcomes Data For Merck’s MK-0524A
The wait for cardiovascular trial’s finish will push back refiling for the niacin/laropiprant combo to 2013.
Prasugrel: To Be (Approved) Or Not To Be
FDA will soon weigh in; the action date for Lilly/Daiichi’s Plavix competitor is June 26.